Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedAug 29, 2025
DataAggregated Company Financials
Companies62
  • 7D1.3%
  • 3M15.5%
  • 1Y-20.9%
  • YTD-9.5%

The Life Sciences industry has been flat over the last week, but Qiagen has lost 6.1%. As for the longer term, the industry has declined 21% in the last year. Earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 29 Aug 2025US$578.9bUS$144.3bUS$14.6b29x39.8x4x
Sun, 27 Jul 2025US$585.5bUS$143.7bUS$8.8b40.1x66.5x4.1x
Tue, 24 Jun 2025US$521.0bUS$142.9bUS$9.2b35.3x56.8x3.6x
Thu, 22 May 2025US$522.0bUS$142.8bUS$9.1b32.1x57.4x3.7x
Sat, 19 Apr 2025US$504.0bUS$142.6bUS$10.0b34.3x50.6x3.5x
Mon, 17 Mar 2025US$597.5bUS$143.1bUS$9.8b38.6x61.2x4.2x
Wed, 12 Feb 2025US$643.4bUS$143.2bUS$11.1b37.2x57.7x4.5x
Fri, 10 Jan 2025US$677.6bUS$142.4bUS$10.2b43.7x66.4x4.8x
Sun, 08 Dec 2024US$664.3bUS$142.4bUS$10.2b44.2x65x4.7x
Tue, 05 Nov 2024US$689.5bUS$142.3bUS$9.0b39.1x76.8x4.8x
Thu, 03 Oct 2024US$752.7bUS$141.8bUS$8.5b39.3x88.6x5.3x
Sat, 31 Aug 2024US$746.6bUS$141.8bUS$8.5b37.8x87.9x5.3x
Mon, 29 Jul 2024US$732.9bUS$141.0bUS$12.6b37.3x58.3x5.2x
Wed, 26 Jun 2024US$696.3bUS$141.3bUS$12.2b38.2x57.2x4.9x
Fri, 24 May 2024US$735.1bUS$141.5bUS$12.4b38.7x59.2x5.2x
Sun, 21 Apr 2024US$681.6bUS$142.0bUS$12.8b40.8x53.3x4.8x
Tue, 19 Mar 2024US$742.5bUS$142.1bUS$12.8b44.3x57.8x5.2x
Thu, 15 Feb 2024US$697.5bUS$142.2bUS$12.8b43x54.3x4.9x
Sat, 13 Jan 2024US$684.9bUS$153.9bUS$14.2b35.4x48.3x4.5x
Mon, 11 Dec 2023US$644.8bUS$153.7bUS$14.0b35.2x46x4.2x
Wed, 08 Nov 2023US$590.2bUS$153.9bUS$11.0b30.9x53.6x3.8x
Fri, 06 Oct 2023US$642.5bUS$154.6bUS$11.2b33x57.4x4.2x
Sun, 03 Sep 2023US$735.8bUS$154.6bUS$11.2b33.1x65.7x4.8x
Tue, 01 Aug 2023US$727.5bUS$154.7bUS$11.6b31.1x62.6x4.7x
Thu, 29 Jun 2023US$680.9bUS$152.4bUS$12.5b29.5x54.4x4.5x
Sat, 27 May 2023US$677.4bUS$152.2bUS$12.5b27.7x54.2x4.5x
Mon, 24 Apr 2023US$728.5bUS$154.6bUS$10.8b29.9x67.4x4.7x
Wed, 22 Mar 2023US$711.8bUS$154.5bUS$10.8b26.7x65.8x4.6x
Fri, 17 Feb 2023US$744.7bUS$154.2bUS$8.6b31.6x86.6x4.8x
Sun, 15 Jan 2023US$761.4bUS$155.3bUS$8.5b30.6x89.3x4.9x
Tue, 13 Dec 2022US$772.2bUS$155.1bUS$8.8b29x88x5x
Thu, 10 Nov 2022US$701.4bUS$154.8bUS$8.9b26.2x79x4.5x
Sat, 08 Oct 2022US$723.9bUS$152.5bUS$17.0b23.8x42.6x4.7x
Mon, 05 Sep 2022US$753.3bUS$152.3bUS$17.3b28.7x43.5x4.9x
Price to Earnings Ratio

43.5x


Total Market Cap: US$753.3bTotal Earnings: US$17.3bTotal Revenue: US$152.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.9x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.0x which is lower than its 3-year average PE of 61.9x.
  • The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 5.7% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.28%
Healthcare-0.28%
Life Sciences1.30%
Clinical Research and Equipment1.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$489.741.2%
+US$2.3b		-19.9%PE28.1x
A Agilent TechnologiesUS$124.966.7%
+US$2.2b		-12.3%PE29x
DHR DanaherUS$205.290.7%
+US$995.3m		-23.1%PE43.1x
IQV IQVIA HoldingsUS$188.731.8%
+US$567.8m		-24.7%PE25.9x
MEDP Medpace HoldingsUS$472.944.3%
+US$550.6m		29.2%PE31.8x

Latest News

A
US$124.96
Agilent Technologies
7D
6.7%
1Y
-12.3%
MEDP
US$472.94
Medpace Holdings
7D
4.3%
1Y
29.2%
TEM
US$73.66
Tempus AI
7D
-4.0%
1Y
27.2%
CRL
US$163.22
Charles River Laboratories International
7D
5.6%
1Y
-18.1%

Advanced Therapeutics Adoption Will Transform Preclinical Capabilities

Charles River Laboratories’ price target was raised to $172.07 following a strong Q2 beat, renewed demand stability, and valuation support from strategic review and activist involvement, partially offset by lingering uncertainty into late 2025. Analyst Commentary Q2 results exceeded expectations with sales 5% above consensus and a significant adjusted EPS beat, indicating improving operational performance.
TMO
US$489.74
Thermo Fisher Scientific
7D
1.2%
1Y
-19.9%

Pharmaceutical And Biotech Expansion Will Fuel Future Success

Analysts raised their price target for Thermo Fisher Scientific to $555.84, citing improved sentiment from strong Q2 results, upward FY25 guidance revisions, and optimism around its resilient pharmaceutical partnership model and recovering end-markets, despite ongoing R&D headwinds. Analyst Commentary Bullish analysts highlight Thermo Fisher's resilient "one-stop-shop" pharma partnership model, expecting it to drive multiple expansion and position the company as a long-term biopharma partner of choice.
OABI
US$1.64
OmniAb
7D
-8.9%
1Y
-61.6%
AVTR
US$13.21
Avantor
7D
5.2%
1Y
-48.8%
QGEN
US$46.14
Qiagen
7D
-6.1%
1Y
-1.8%
ICLR
US$175.05
ICON
7D
-0.4%
1Y
-45.4%

After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar

Aug 20
After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar
RVTY
US$89.23
Revvity
7D
-0.5%
1Y
-27.0%

Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings Suggest

Aug 14
Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings Suggest
DHR
US$205.29
Danaher
7D
0.7%
1Y
-23.1%
ILMN
US$99.17
Illumina
7D
-0.1%
1Y
-25.9%

Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues
BRKR
US$33.46
Bruker
7D
-1.0%
1Y
-50.5%

Renewed Biopharma Funding And Cost Savings Will Revitalize Markets

Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).
WAT
US$297.65
Waters
7D
2.5%
1Y
-13.7%
RGEN
US$122.17
Repligen
7D
-2.1%
1Y
-19.1%
IQV
US$188.73
IQVIA Holdings
7D
1.8%
1Y
-24.7%